Company profile
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LENABASUM | phase2 | — | 3 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07310901 | phase1 | active_not_recruiting | 2025-12-04 | 2026-07-02 | Corbus Pharmaceuticals Inc. | A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity |
| NCT06265727 | phase1_2 | recruiting | 2024-04-01 | 2027-01-16 | Corbus Pharmaceuticals Inc. | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors |
| NCT07768189 | phase3 | not_yet_recruiting | 2026-09-20 | 2027-12-01 | Corbus Pharmaceuticals Inc. | A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma |
| NCT06603844 | phase1_2 | recruiting | 2024-12-04 | 2026-11-01 | Corbus Pharmaceuticals Inc. | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. |
| NCT02465437 | phase2 | terminated | 2015-08-01 | 2016-10-01 | Corbus Pharmaceuticals Inc. | Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis |
FDA applications (0)
No records yet.